BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,122,372 | -16.2% | 45,870 | +0.5% | 0.01% | -12.5% |
| Q2 2023 | $3,723,961 | +10.0% | 45,620 | 0.0% | 0.01% | +14.3% |
| Q1 2023 | $3,384,548 | -0.9% | 45,620 | +10.7% | 0.01% | -12.5% |
| Q4 2022 | $3,416,314 | +6.6% | 41,220 | +265.4% | 0.01% | 0.0% |
| Q3 2022 | $3,204,000 | -18.5% | 11,280 | -0.5% | 0.01% | -11.1% |
| Q2 2022 | $3,929,000 | -18.9% | 11,335 | +1.4% | 0.01% | -10.0% |
| Q1 2022 | $4,842,000 | -27.3% | 11,180 | -13.1% | 0.01% | -23.1% |
| Q4 2021 | $6,658,000 | +650.6% | 12,870 | +603.7% | 0.01% | +550.0% |
| Q3 2021 | $887,000 | -94.2% | 1,829 | -94.6% | 0.00% | -93.5% |
| Q2 2021 | $15,393,000 | +17.9% | 34,186 | 0.0% | 0.03% | +10.7% |
| Q1 2021 | $13,057,000 | +38.5% | 34,186 | +15.2% | 0.03% | +33.3% |
| Q4 2020 | $9,427,000 | +28.2% | 29,686 | 0.0% | 0.02% | +10.5% |
| Q3 2020 | $7,354,000 | -1.2% | 29,686 | +5.3% | 0.02% | -5.0% |
| Q2 2020 | $7,443,000 | +40.2% | 28,186 | +0.7% | 0.02% | +11.1% |
| Q1 2020 | $5,307,000 | -13.6% | 27,986 | 0.0% | 0.02% | +12.5% |
| Q4 2019 | $6,143,000 | – | 27,986 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |